NEW THIS WEEK

Congratulations 2018 Residency Research and Summer Medical Student Fellowship Awardees!

The AUA and the Urology Care Foundation— the official foundation of the AUA—are delighted to announce the newest Residency Research and Summer Medical Student Fellowship Awardees! Residency Research Awards, made possible by the Russell Scott, Jr., MD Urology Research Fund, support either six months or one year of research under the direction of an accomplished mentor. Summer Medical Student Fellowships enable medical students to undertake a ten-week mentored research experience alongside world-class urologic scientists. The awards are sponsored by the Arkansas Urologic Society, the Florida Urological Society, and the Herbert Brendler, MD Research Fund. The 2019 competition for both awards will open this fall.

Many Men with Penile Cancer Do Not Get Recommended Treatments

Not all men with penile cancer that has spread to nearby lymph nodes receive recommended treatments that could improve their survival, according to a large retrospective study published in JAMA Oncology. Using records from a national cancer treatment database, researchers found that about one-third of these men did not have affected lymph nodes removed and less than half had chemotherapy.

IN THE AUA

NIDDK/AUA Workshop on Congenital Anomalies of External Genitalia - Save the Date

The Congenital Anomalies of External Genitalia Workshop will be held on May 31 - June 1, 2018 at AUA Headquarters in Linthicum, MD. This two-day meeting will bring together researchers from a range of disciplines, including pediatric urology, developmental biology, genetics & genomics, biomechanics, endocrinology, and epidemiology, with the goal of advancing basic and clinical research in hypospadias and related disorders of external genital development. Presentations and roundtable discussions of current research strategies will aim to identify key knowledge gaps and missed opportunities and to develop potential investigative solutions that will address deficiencies in the field. Basic and clinical researchers interested in the causes of hypospadias and related congenital anomalies of external genitalia are encouraged to attend. Please contact research@auanet.org with any questions.
Save the Date - "Cellular Functions in Urology" hosted by the University of Wisconsin-Madison O'Brien Center

The George M. O'Brien Urology Research Center at the University of Wisconsin-Madison will hold its Spring Symposium titled “Cellular Functions in Urology” on **April 20-21, 2018 at the University of Wisconsin in Madison, WI.** For more information, please contact Dr. Will Ricke at wricke@wisc.edu or Shana Peterson at peterson@urology.wisc.edu.

Multidisciplinary Benign Urology Research Day

The Multidisciplinary Benign Urology Research Day is sponsored by the Duke Multidisciplinary K12 Urologic Research Career Development Program (KURe) and the Duke Pelvic Medicine Research Consortium (PMRC). The event will be held on **May 11, 2018 at Duke University in Durham, North Carolina.** Panel discussions include urinary stone disease and the role of environmental exposures and lifestyle in genitourinary development and disease. Research and clinicians from any discipline are encouraged to attend. The event will also provide opportunities for oral and poster presentations, trainee awards, and lunch with experts.

Register Now

Third Global Summit on Precision Diagnosis and Treatment of Prostate Cancer - AdMeTech Foundation

The Third Global Summit on Precision Diagnosis and Treatment of Prostate Cancer will be held in **Boston, MA on August 3-5, 2018.** This meeting is a unique multi-disciplinary forum organized to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of observation strategies (e.g., active surveillance) and novel therapeutic interventions. The goal is to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The Third Global Summit will build on the success of the First and Second Global Summits, which have emerged as the seminal events in recognizing radiogenomics – integrating imaging and molecular diagnostics – as the future of patient care.

Learn More

FUNDING OPPORTUNITIES

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)

The purpose of the **Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)** is to support research training of highly promising postdoctoral candidates who have the potential to become productive, independent investigators in scientific health-related research fields relevant to the missions of the participating NIH Institutes and Centers. Applications are expected to incorporate exceptional mentorship. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor. **The application deadline is April 8, 2018.**
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)

The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) award is to enable promising predoctoral students to obtain individualized, mentored research training from outstanding faculty sponsors while conducting dissertation research in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training must reflect the applicant's dissertation research project and is expected to clearly enhance the individual's potential to develop into a productive, independent research scientist. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor. The application deadline is April 8, 2018.

Specialized Centers of Research Excellence (SCORE) on Sex Differences (U54 Clinical Trial Optional)

The Office of Research on Women’s Health and participating organizations and institutes seek applications for Specialized Centers of Research Excellence (SCORE) on Sex Differences. The Centers of Excellence will support interdisciplinary approaches to advance translational research on sex differences. Each SCORE institution should develop a research agenda bridging basic and clinical research underlying a health issue that is pertinent to improving the health of women. The application deadline is April 16, 2018.

2018 PCF Challenge Awards for Metastatic, Lethal Prostate Cancer

The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. High risk, currently unfunded projects are most desired. PCF especially seeks applications conducting research in VA hospitals where research directly affects veterans with advanced prostate cancer. The Movember Foundation will fund approximately three (3) Movember Foundation-PCF Challenge Awards from U.S.-based teams with money it has raised in the U.S. Other funding sources will support additional PCF Challenge Awards at institutions from within or outside the U.S. The application deadline is April 23, 2018.

Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. The FOA is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control. **The application deadline is June 5, 2018.**

---

**High Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional)**

This Funding Opportunity Announcement (FOA) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that addresses high priority HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities are described in [NOT-OD-15-137: NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding](#). **The application deadline is June 5, 2018.**

---

**NIH Underactive Bladder and Detrusor Activity in Aging**

The NIH has released three Funding Opportunity Announcements (FOAs) inviting applications that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. Research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons. **View the FOAs below!**

- [R01 Clinical Trial Optional](#) - Application deadline: June 5, 2018.
- [R03 Clinical Trial Optional](#) - Application deadline: June 16, 2018.
- [R21 Clinical Trial Optional](#) - Application deadline: June 16, 2018.

---

**National Centers for Translational Research in Reproduction and Infertility (P50 Clinical Trial Optional)**

The purpose of this FOA is to announce the re-competition of the National Centers for Translational Research in Reproduction and Infertility (NCTRI). For the purpose of this FOA, reproductive health includes both fertility/infertility and gynecological health. The NCTRI will be administered through the Specialized Research Center (P50) award mechanism. These centers will form a national network that facilitates and accelerates bidirectional knowledge transfer between the laboratory and clinic with the ultimate goal of improving human reproductive and gynecological health through research excellence and innovation. For this FOA, applications that address the epigenetic bases of reproductive health will be strongly encouraged. Particular emphasis will be on applications that go beyond correlative studies to address possible causality and contributions of epigenomic variants to inherited reproductive health and disease. **The application deadline**
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. The application deadline is June 5, 2018.